TRENDING TOPICS
760 articles found for "passive income"
Disney announces it will no longer disclose Disney+ and Hulu subscriber counts, signaling a fundamental shift in how streaming companies measure and communicate success.
Amazon reports Q4 2025 results with revenue of $180 billion and AWS reaching $132 billion annualized run rate as AI demand pushes cloud backlog to unprecedented levels.
Once left for dead, Peloton has quietly strung together two consecutive profitable quarters and generated $67 million in free cash flow. Thursday's earnings will reveal if the turnaround is sustainable.
Disney's theme parks, resorts, and cruises division has achieved a historic milestone, generating over $10 billion in quarterly revenue for the first time as the entertainment giant's physical experiences outpace expectations.
ARM Holdings reports fiscal Q4 2026 earnings after market close, seeking its ninth consecutive earnings beat as Wall Street watches licensing revenue for AI demand signals.
Phillips 66 reports Q4 earnings of $2.47 per share, beating estimates by 15%, as refining crack spreads improve 45% and the company achieves record 88% clean product yield.
CME Group reports $6.5 billion in 2025 revenue with record trading volumes of 28.1 million contracts per day as cryptocurrency and micro contract trading surge.
GE HealthCare beats Q4 earnings estimates with EPS of $1.44 and announces record backlog of $21.8 billion as AI-powered imaging devices gain FDA clearance.
UBS reported Q4 profit of $1.2 billion, beating estimates by 31%, and announced $3 billion in share buybacks for 2026. Assets under management exceed $7 trillion for the first time.
The ISM Services PMI rose to 55.2 in January 2026, beating expectations and pointing to accelerating expansion in the services sector that drives most of the U.S. economy.
Uber reports Q4 2025 revenue of $14.5 billion, beating estimates, as CEO Dara Khosrowshahi outlines a vision for integrating autonomous vehicles into the ride-hailing platform.
AbbVie delivers better-than-expected Q4 2025 earnings as immunology blockbusters Skyrizi and Rinvoq more than offset the biosimilar erosion of former cash cow Humira.